Close menu




Covid19

Photo credits: pixabay.com

Commented by Armin Schulz on January 30th, 2024 | 06:30 CET

BioNTech, Cardiol Therapeutics, Evotec - Biotech upswing post-Corona

  • Biotechnology
  • Covid19
  • Biotech

After the hype caused by the Corona vaccines, many biotech companies experienced a lull. However, there are now increasing signs of a revival, and with good reason. After a period of stagnation caused by market saturation and investor reluctance, fresh scientific breakthroughs and innovative therapeutic approaches are attracting investors and driving the sector to new heights. German biotech companies have managed to raise more funds than in the previous year despite the challenging conditions in the financial markets. Today, we look at three interesting companies and highlight their opportunities for this year.

Read

Commented by André Will-Laudien on January 15th, 2024 | 06:45 CET

Biotech: Corona is back! The doublers are lurking here: BioNTech, Evotec, Defence Therapeutics and Bayer

  • Biotechnology
  • Pharma
  • Covid19

We had almost forgotten about Corona and the good old flu, but it is back in full swing. Governments are remaining calm and holding on to their regained liberalism. However, Spain is now resorting to drastic measures again to protect vulnerable population groups. A mask is to be compulsory again in all Spanish healthcare facilities due to the increase in respiratory diseases. Health Minister Mónica García had previously failed to convince the Spanish regions of the need to introduce compulsory masks of their own accord. In some parts of the country, hospital emergency rooms are under severe pressure due to high patient numbers. Biotech stocks are showing the first signs of recovery after the sell-off in 2023. We take a look at a few selected stocks with 100% potential.

Read

Commented by Armin Schulz on December 12th, 2023 | 06:50 CET

BioNTech, Defence Therapeutics, Bayer - Golden times for the biotech and pharma industry?

  • Biotechnology
  • Pharma
  • Covid19

With the arrival of winter, people are increasingly worried about illnesses such as coronavirus and influenza. The current wave of diseases and the new coronavirus variant are increasing the demand for medicines, which could positively impact the shares of pharmaceutical and biotech companies. Biotech's success in drug development for COVID-19 vaccines has allowed the industry to flourish over the past two years. But after the boom came the crash. However, the stock market always moves in cycles. The current challenges in the healthcare sector, such as the rising number of cancer cases, could, therefore, mean golden times for pharmaceutical and biotech companies, as they not only contribute to improving global health but also offer attractive returns for investors.

Read

Commented by André Will-Laudien on November 7th, 2023 | 07:00 CET

Caution: New Corona wave ahead? BioNTech, Pfizer, Cardiol Therapeutics and MorphoSys on the performance test bench

  • Biotechnology
  • Pharma
  • Covid19

Smouldering lawsuits from vaccinated patients experiencing severe side effects have caused investors to doubt BioNTech and Pfizer in recent months. Will the plaintiffs be successful in court? This is rather unlikely, as the vaccine manufacturers can always invoke the time component in the fight against the pandemic. After all, what the WHO and all governments wanted was delivered: A quick solution! Moreover, these vaccines were finally approved by well-known health institutes. The biotech investment segment will become exciting again as winter approaches. The infection figures with the new coronavirus variants are rising noticeably again, and around 15% of the population wishes to get vaccinated. Where are the opportunities for investors?

Read

Commented by Armin Schulz on September 6th, 2023 | 08:00 CEST

BioNTech, Cardiol Therapeutics, Bayer - Tiger mosquitoes, and rising Corona numbers bring biotech back in focus

  • Biotechnology
  • Cancer
  • Covid19

Corona infections are already rising, even though autumn has not even begun. Hospitals are already fearing a high burden during the winter. Gerald Gaß, the Chairman of the Board of the German Hospital Federation, advised high-risk patients, their close contacts and healthcare workers to keep their flu and COVID-19 vaccinations up to date. Due to constant stress triggered by crises and workload-related pressures, the number of heart patients have also increased in recent years. At the end of August, entire neighborhoods and streets in Paris were closed off to spray insecticides against tiger mosquitoes, which spread diseases like dengue and Zika viruses, among others. This is reason enough for us to examine three companies fighting these threats.

Read

Commented by André Will-Laudien on March 15th, 2023 | 17:38 CET

Bayer, BioNxt, BioNTech - Biotech is on the rise again, bring on the blockbusters!

  • Biotechnology
  • vaccine
  • Covid19

The time of the vaccine producers is over because the willingness to vaccinate is declining worldwide. As a result, the entire biotech sector has entered a strong correction phase since the pandemic mode for COVID-19 ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Complicating matters for companies is the significant increase in interest rates for long-term financing of their pipelines. When refinancing costs rise, this often leads to lower valuations. However, some companies are impressing with their innovations and have recently shown significant outperformance to the market. We evaluate the opportunities of some well-known biotech protagonists!

Read

Commented by Stefan Feulner on March 1st, 2023 | 14:01 CET

BioNTech, BioNxt Solutions, Bayer - Turn of the tide

  • Biotechnology
  • Covid19

Just how fundamental biotechnology already is for humanity was demonstrated by the development of the various COVID vaccines, which was extremely rapid by historical standards. Previously unknown companies such as BioNTech, Valneva and CureVac came into the focus of the stock market and were able to multiply within a very short time. Even after the pandemic has ended, research in the biotech sector is running at full speed. This is giving rise to new, innovative growth companies that could follow a similar trajectory in the future.

Read

Commented by Juliane Zielonka on February 10th, 2023 | 18:56 CET

Defence Therapeutics, Bayer, BioNTech - US investors love biotech stocks

  • Biotechnology
  • Covid19

US investors love biotech companies. So it is thanks to pressure from investor Jeff Ubben that Bayer AG's leadership is changing a year earlier than planned. Shareholders welcome the decision, with Bayer's share price rising a whopping 5% this week. The fight against cancer is the mission of the Canadian company Defence Therapeutics. They have taken another critical step forward in the pipeline to bring their cancer therapy to solid tumors. BioNTech co-founder Ugur Sahin is also showing commitment. The Turkish-born physician actively supports the crisis regions of the earthquakes in his home country and Syria. Find out how this relates to the Group's profits here.

Read

Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

  • Biotechnology
  • Cancer
  • Covid19
  • Investments

Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

Read

Commented by Stefan Feulner on January 12th, 2023 | 14:33 CET

Powerful movements in the biotech sector - CureVac, Cardiol Therapeutics, Ambrx Biopharma

  • Biotechnology
  • Covid19
  • Cancer

That the biotech sector stands for high volatility is nothing new. Price jumps of more than 50% in one day after study results are no exception. Last year, the capital-intensive sector of the future suffered from the change in strategy by the central banks with several interest rate hikes. The Nasdaq Biotech Index alone lost around 50% of its value in some cases. In addition, smaller stocks that do not yet have a commercial product on the market experienced massive upheavals. The speed with which a rebound can set in was demonstrated not only by vaccine producer CureVac.

Read